629 related articles for article (PubMed ID: 31638892)
21. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.
Choi J; Kim GA; Han S; Lee W; Chun S; Lim YS
Hepatology; 2019 May; 69(5):1983-1994. PubMed ID: 30153338
[TBL] [Abstract][Full Text] [Related]
22. Serum alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.
Kuromatsu R; Tanaka M; Tanikawa K
Liver; 1993 Aug; 13(4):177-82. PubMed ID: 7690873
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
24.
Lee HA; Lee YR; Lee YS; Jung YK; Kim JH; An H; Yim HJ; Jeen YT; Yeon JE; Byun KS; Seo YS
World J Gastroenterol; 2021 Jul; 27(28):4687-4696. PubMed ID: 34366629
[TBL] [Abstract][Full Text] [Related]
25. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.
Yamamoto K; Imamura H; Matsuyama Y; Kume Y; Ikeda H; Norman GL; Shums Z; Aoki T; Hasegawa K; Beck Y; Sugawara Y; Kokudo N
J Gastroenterol; 2010 Dec; 45(12):1272-82. PubMed ID: 20625772
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of alpha-fetoprotein,
Song T; Wang L; Su B; Zeng W; Jiang T; Zhang T; Sun G; Wu H
J Int Med Res; 2020 Mar; 48(3):300060519889270. PubMed ID: 31852373
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
29. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
30. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma.
Liu Z; Wu M; Lin D; Li N
J Int Med Res; 2020 Feb; 48(2):300060520902575. PubMed ID: 32054358
[TBL] [Abstract][Full Text] [Related]
31. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.
Jitpraphawan O; Ruamtawee W; Treewatchareekorn M; Sethasine S
World J Gastroenterol; 2024 May; 30(17):2343-2353. PubMed ID: 38813057
[TBL] [Abstract][Full Text] [Related]
33. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
34. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
35. Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma.
Tameda M; Shiraki K; Sugimoto K; Ogura S; Inagaki Y; Yamamoto N; Ikejiri M; Takei Y; Ito M; Nobori T
Cancer Sci; 2013 Jun; 104(6):725-31. PubMed ID: 23480217
[TBL] [Abstract][Full Text] [Related]
36. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ⩽5 cm: Cohort study based on serum HCC markers.
Ueno M; Hayami S; Shigekawa Y; Kawai M; Hirono S; Okada K; Tamai H; Shingaki N; Mori Y; Ichinose M; Yamaue H
J Hepatol; 2015 Dec; 63(6):1352-9. PubMed ID: 26212030
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma.
Jang ES; Jeong SH; Kim JW; Choi YS; Leissner P; Brechot C
PLoS One; 2016; 11(3):e0151069. PubMed ID: 26986465
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
Gao F; Zhu HK; Zhu YB; Shan QN; Ling Q; Wei XY; Xie HY; Zhou L; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):371-7. PubMed ID: 27498576
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
